Tag archive for ‘multiple sclerosis’
Jewish Business News On Friday, June 23rd, 2017

Israeli Study Reveals Possible Trigger for Multiple Sclerosis

Multiple sclerosis, one of the most devastating neurodegenerative diseases, affects some 2.5 million people worldwide and has no known cure. Researchers have long speculated that Multiple sclerosis is triggered More...

Jewish Business News On Monday, October 17th, 2016

New study links protein in wheat to chronic inflammation conditions

  Scientists have discovered that a family of proteins found in wheat triggers the inflammation of chronic health conditions, such as multiple sclerosis, asthma and rheumatoid arthritis, and also More...

Teva receives approval to market Copaxone in Japan

  Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) announced today that the the Japanese Ministry of Health, Labour and Welfare has approved once-daily Copaxone (glatiramer acetate injection) More...

Jewish Business News On Sunday, July 19th, 2015

Cannabis may be used to treat fractures

Cannabis — marijuana, hashish– was used as a go-to medical remedy by societies around the world for centuries. But the therapeutic use of marijuana was banned in most countries in the 1930s and More...

Galmed Enters Manufacturing Agreement with Perrigo for Aramchol

Israel’s Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral medication for the treatment of liver diseases and More...

Globes On Monday, January 26th, 2015

Teva gets first “Sell” recommendation

Berenberg analysts see insurance companies pressuring MS patients to switch to generic versions of Copaxone. Last year, Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) posted its highest return More...

Nadav Neuman On Wednesday, January 21st, 2015

US Supreme Court upholds Copaxone patent

The ruling means Teva’s flagship multiple sclerosis treatment’s patent remains valid until September 2015.   The US Supreme Court has ruled in favor of Teva Pharmaceutical Industries Ltd. (NYSE: More...

Shiri Habib-Valdhorn On Sunday, November 30th, 2014

FDA again delays decision on Copaxone patent

– The decision gives Teva more time to transfer patients to its better patent protected double dosage Copaxone. – Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) has filed a petition More...

Gil Tanenbaum On Thursday, November 13th, 2014

Teva’s MS Drug Copaxone Looking for Approval in Japan

Teva’s Copaxone, a new medication under development for the treatment of multiple sclerosis treatment Copaxone, has gotten closer to getting approval for marketing in Japan from that nation’s regulatory More...

Vered Weiss On Thursday, October 16th, 2014

Initial U.S. Supreme Court Hearing Mixed on Teva’s Pharmaceuticals Patent Protection

– Leading Israeli Pharmaceutical company Teva has mixed results in its initial U.S. Supreme Court hearing over the possible loss of patent protection for Copaxone, a multiple sclerosis drug that accounts More...

Wordpress site Developed by Fixing WordPress Problems